Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide

Journal of Experimental Medicine

Volumn 194, Issue 6, 2001, Pages 833-846

  Tangri, S ^a   Ishioka, G Y ^a   Huang, X ^a   Sidney, J ^a   Southwood, S ^a   Fikes, J ^a   Sette, A ^a  

^a Epimmune   (United States)

Author keywords

Amino acid substitutions; CTL; Heteroclitic analogs; MHC; Vaccine

Indexed keywords

AMINO ACID; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERLEUKIN 10; INTERLEUKIN 5; PEPTIDE DERIVATIVE; TUMOR ANTIGEN; VIRUS ANTIGEN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; CARCINOEMBRYONIC ANTIGEN; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, POL; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV-1; HLA-A2 ANTIGEN; HT29 CELLS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-5; JURKAT CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE BIOSYNTHESIS; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0035903287     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.194.6.833     Document Type: Article

References (50)

1. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses
2. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
3. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
4. Analogues of CTL epitopes with improved MHC class I binding capacity elicit anti-melanoma CTL recognizing the wildtype epitope
5. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen
6. + T cell clones reactive to Melanoma/Melanocyte epitope MART-1
7. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR, complex
8. Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues
9. The stimulation of low-affinity non-tolerized clones by heteroclitic antigen analogues causes the breaking of tolerance established to an immunodominant T cell epitope
10. b transgenic mice
11. + T cells with enhanced functional characteristics: Implication for more effective immunotherapy
12. + T cells by antigenic peptides altered for TCR binding
13. Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of Tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide
14. Tuning T cell activation threshold and effector function with cross-reactive peptide ligands
15. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cell, B7 costimulation and T helper cell 1-associated cytokines
16. Peptide pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity
17. Lymphokine production by human T cells in disease states
18. Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules
19. An HLA-A2 tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel pathway for processing of membrane proteins
20. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes
21. Exploring immunological specificity using synthetic peptide combinatorial libraries
22. Tumor antigens recognized by T lymphocytes
23. Major histocompatibility complex class I allele-specific peptide libraries: Identification of peptides that mimic an H-Y T cell epitope
24. The multi-epitope approach for immunotherapy of cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors
25. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes
26. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
27. A model for evolutionary change
28. Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins
29. A simple method for displaying the hydropathic character of a protein
30. Hydrophobic parameters pi of amino-acid side chains from the partitioning of N-acetylamino-acid amides
31. Amino acid, peptide, and protein volume in solution
32. Protein volume in solution
33. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays
34. Analysis of the HLA-restricted influenza specific cytotoxic T lymphocyte responses in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex
35. Characterization of an in situ IFN-γ ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization
36. Counting antigen-specific CD8 T cells: A re-evaluation of bystander activation during viral infection
37. + T-cell frequencies by the ELISPOT assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
38. Identification of HLA-A*0201 restricted CTL epitopes encoded by the tumor specific MAGE-2 gene product
39. Heterocliric immunization induces tumor immunity
40. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A201 binding residues
41. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
42. Ligand recognition by alpha beta T cell receptors
43. Targeting p53 as a general tumor antigen
44. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes
45. The three-dimensional structure of peptide-MHC complexes
46. The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2
47. Autoantigen recognition by human CD8 T cell clones
48. TCR-independent pathways mediate the effects of antigen dose and altered peptide ligands on Th cell polarization